Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in patients hospitalized with COVID-19: long-term results from the DisCoVeRy trial. - Massonnaud CR; Peiffer-Smadja N; Poignard P; Jamard S; Goehringer F; Danion F; Reignier J; de Castro N; Garot D; Lapique EL; Lacombe K; Tolsma V; et al. (Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2026)